

OPEN ACCESS

Edited by:

Choel Kim, Baylor College of Medicine, United States

Reviewed by:

Thomas Söllner, Heidelberg University, Germany Nils Brose, Max Planck Institute for Multidisciplinary Sciences, Germany

*Correspondence:

Axel T. Brunger brunger@stanford.edu Ying Lai ylai@scu.edu.cn Burton F. Dickey bdickey@mdanderson.org

[†]Present Address:

Ying Lai State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu China John Peters Harvard Medical School, Boston, MA, United States Qiangjun Zhou Department of Cell and Developmental Biology, Center for Structural Biology, Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN, United States

Specialty section:

This article was submitted to Respiratory Pharmacology, a section of the journal Frontiers in Pharmacology

Received: 07 March 2022 Accepted: 14 April 2022 Published: 17 June 2022

Citation:

Lai Y, Tuvim MJ, Leitz J, Peters J, Pfuetzner RA, Esquivies L, Zhou Q, Czako B, Cross JB, Jones P, Dickey BF and Brunger AT (2022) Screening of Hydrocarbon-Stapled Peptides for Inhibition of Calcium-Triggered Exocytosis. Front. Pharmacol. 13:891041. doi: 10.3389/fphar.2022.891041

Screening of Hydrocarbon-Stapled Peptides for Inhibition of Calcium-Triggered Exocytosis

Ying Lai^{1*†}, Michael J. Tuvim², Jeremy Leitz¹, John Peters^{1†}, Richard A. Pfuetzner^{1,3}, Luis Esquivies^{1,3}, Qiangjun Zhou^{1†}, Barbara Czako⁴, Jason B. Cross⁴, Philip Jones⁴, Burton F. Dickey^{2*} and Axel T. Brunger^{1,3*}

¹Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA, United States, ²Department of Pulmonary Medicine, MD Anderson Cancer Center, University of Texas, Houston, TX, United States, ³Howard Hughes Medical Institute, Stanford University, Stanford, CA, United States, ⁴Institute for Applied Cancer Science, MD Anderson Cancer Center, University of Texas, Houston, TX, United States

The so-called primary interface between the SNARE complex and synaptotagmin-1 (Syt1) is essential for Ca²⁺-triggered neurotransmitter release in neuronal synapses. The interacting residues of the primary interface are conserved across different species for synaptotagmins (Syt1, Syt2, Syt9), SNAP-25, and syntaxin-1A homologs involved in fast synchronous release. This Ca²⁺-independent interface forms prior to Ca²⁺-triggering and plays a role in synaptic vesicle priming. This primary interface is also conserved in the fusion machinery that is responsible for mucin granule membrane fusion. Ca²⁺-stimulated mucin secretion is mediated by the SNAREs syntaxin-3, SNAP-23, VAMP8, Svt2, and other proteins. Here, we designed and screened a series of hydrocarbon-stapled peptides consisting of SNAP-25 fragments that included some of the key residues involved in the primary interface as observed in high-resolution crystal structures. We selected a subset of four stapled peptides that were highly α -helical as assessed by circular dichroism and that inhibited both Ca²⁺-independent and Ca²⁺-triggered ensemble lipid-mixing with neuronal SNAREs and Syt1. In a single-vesicle content-mixing assay with reconstituted neuronal SNAREs and Syt1 or with reconstituted airway SNAREs and Syt2, the selected peptides also suppressed Ca²⁺-triggered fusion. Taken together, hydrocarbon-stapled peptides that interfere with the primary interface consequently inhibit Ca²⁺-triggered exocytosis. Our inhibitor screen suggests that these compounds may be useful to combat mucus hypersecretion, which is a major cause of airway obstruction in the pathophysiology of COPD, asthma, and cystic fibrosis.

Keywords: mucin secretion, neurotransmitter release, stimulated membrane fusion, stapled peptide, airway obstruction, asthma, cystic fibrosis

INTRODUCTION

SNARE-mediated membrane fusion is a ubiquitous mechanism for many biological processes, wherein zippering of the SNARE complex drives membranes together and leads to membrane fusion (Südhof, 2013; Rothman, 2014; Brunger et al., 2018). For Ca^{2+} -triggered membrane fusion, SNAREs must cooperate with Ca^{2+} sensors. For example, the neuronal SNARE complex (consisting of synaptobrevin-2/VAMP-2, syntaxin-1A (Stx1), and SNAP-25A) forms a specific interface with the

1

Ca²⁺-binding C2B domain of synaptotagmin-1 (Syt1) (Zhou et al., 2015; Zhou et al., 2017). The primary interface is conserved in fast synchronous neurotransmitter release (Zhou et al., 2015; Zhou et al., 2017). This interface forms prior to Ca²⁺-triggering during synaptic vesicle priming. Ca²⁺-binding to Syt1 remodels or dissociates the primary complex, likely also involving membrane deformation to promote fusion (Zhou et al., 2015; Zhou et al., 2017). Disruption of the primary SNARE-Syt1 complex interface by mutations abolished fast synchronous release in cultured neurons and greatly reduced the Ca²⁺-triggered amplitude in single-vesicle fusion experiments. Moreover, the primary interface has been observed in solution by nuclear magnetic resonance (NMR) and fluorescence spectroscopy experiments (Voleti et al., 2020), and it is stabilized by interactions with the plasma membrane.

The primary interface is predicted to be conserved well beyond the neuronal exocytosis machinery (Zhou et al., 2015). Here, we additionally focus on the airway epithelial exocytic machinery because of the role of Ca²⁺-stimulated secretion in lung pathobiology. Rapid secretion of highly produced mucins overwhelms the hydration capacity of the airways, resulting in concentrated mucus that is excessively viscoelastic and adhesive. Such concentrated mucus cannot be propelled by ciliary beating, adheres to the airway wall, and occludes the airway lumen. This results in airflow obstruction and lung inflammation in common lung diseases including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (Fahy and Dickey, 2010; Boucher, 2019). Airway mucins are secreted both at a low baseline rate that promotes effective mucociliary clearance, and a high stimulated rate that can lead to the pathology described above. In recent years, molecular components mediating these two modes of secretion have been identified (Davis and Dickey, 2008; Fahy and Dickey, 2010; Jaramillo et al., 2018) and as in neurons, these include SNAREs, and Munc18, Munc13, and synaptotagmins, as follows.

Both baseline and stimulated mucin secretion are impaired in SNAP-23 heterozygous mutant mice (Ren et al., 2015), VAMP8 knock-out mice (Jones et al., 2012), and Munc13-2 knock-out mice (Zhu et al., 2008). In contrast, stimulated mucin secretion is selectively impaired in Munc18-2 and Syt2 deletant mice (Tuvim et al., 2009; Kim et al., 2012; Jaramillo et al., 2019), whereas baseline secretion is selectively impaired in Munc18-1 deletant mice (Jaramillo et al., 2019). Syntaxin-3 (Stx3) binds and colocalizes with Munc18-2 in barrier epithelia (Riento et al., 1998), and immunoprecipitation of Stx3 in airway secretory cells pulls down Munc18-2 (Kim et al., 2012). Thus, we hypothesize that the primary interface in stimulated mucin secretion forms between synaptotagmin-2 (Syt2) and the airway SNARE complex consisting of VAMP8, Stx3, and SNAP-23. Antagonism of this interaction while leaving homeostatic baseline mucin secretion intact could have therapeutic value in muco-obstructive lung diseases.

Many of the residues that are involved in the primary neuronal interface are contributed by the N-terminal α -helix of SNAP-25 that forms one of the four α -helices in the ternary SNARE

complex (Sutton et al., 1998; Zhou et al., 2015). Theoretically, peptides derived from this region of SNAP-25 could be used to specifically interfere with the primary SNARE-Svt1 interface. However, small peptides are typically unstructured and their efficacy as an inhibitor may be inefficient in the absence of helical structure. In this work, to induce a-helical structure, we use non-natural amino acids containing olefin-bearing groups to generate hydrocarbon-stapled peptides by a ring-closing metathesis reaction using a Grubbs catalyst. We designed 12 stapled peptides and tested them with lipid-mixing fusion assays. A subset of these stapled peptides that exhibited the highest ahelicity disrupted Ca²⁺-triggered exocytosis using single-vesicle content-mixing assays with either reconstituted neuronal SNAREs and Syt1 or with reconstituted airway SNAREs and Syt2. Taken together, our hydrocarbon-stapled peptides can be used to reduce both stimulated neurotransmitter release and mucin secretion.

RESULTS

Design and Characterization of Stapled Peptides

Since the primary interface is critical for Ca²⁺-triggered exocytosis (Zhou et al., 2015), it should be possible to interfere with this process by disrupting this protein-protein interface with a suitable compound. We designed a series of hydrocarbonstapled peptides with varying lengths (16-22 amino acids), named SP1-SP12, that cover various portions of this interface of the N-terminal a-helix of SNAP-25A that is involved in the primary interface with Syt1 (Figures 1A,B). The positions of non-natural amino acid substitutions (S5 and R8 olefinic sidechains) were chosen to be away from the primary interface (Figure 1C). We also used slightly different start and end positions within the SNAP-25A sequence that interacts with Syt1 (Figure 1B). The hydrocarbon-staples were made to bridge three (S5 substitution positions i and i+4) or six (R8) substitution positions i and i+7) amino acids within the peptides. As a control, we used a linear peptide (P0) that corresponds to residues 37-58 of SNAP-25A. Liquid chromatography mass spectrometry of the synthesized peptides indicated molecular weights that were close to their predicted molecular weights (Supplementary Figures S1-S12), suggesting that the synthesized peptides have the correct sequence and properly formed staples.

Circular dichroism spectroscopy revealed that the nonstapled P0 peptide displays only 5% α -helicity in solution and presumably forms a random coil (**Figure 1D**). In contrast, many of the stapled peptides had substantially higher α -helical content. Some of the stapled peptides with two hydrocarbon staples have the highest α -helicity (in particular, SP1, SP4, SP9, and SP10), with an α -helical content up to 86% (**Figure 1E**). Note, however, that one of the stapled peptides with two hydrocarbon staples has lower α helicity (SP11). None of the peptides aggregated as assessed by size exclusion chromatography (**Figure 1F**); the differences in retention times are likely related to differences in shape or



cross-linking the residues at the specified positions. P0 is the wildtype sequence for SNAP-25A, residues 37–58. **(B)** Design of synthesized stapled peptides with varying lengths of olefinic side chains and different positions. P0 is the wildtype sequence for SNAP-25A, residues 37–58. **(B)** Design of synthesized stapled peptides with varying lengths of olefinic side chains and different positions of the non-natural amino acid substitutions. The superscripts specify the starting and end positions within the SNAP-25A sequence. *Sn* or *Rn* indicates *S* or *R* stereochemistry at the α -carbon, respectively, *n* indicates the number of carbon atoms in the olefinic side chains. **(C)** Close-up view of the primary interface between the neuronal SNARE complex (VAMP-2—blue, Stx1—red, SNAP-25A—green) and the C2B domain of Syt1 (orange) (PDB ID 5W5C), indicating the region (yellow) from which the peptides were chosen. The C α -positions of the *S5* and *R7* non-natural amino acid substitutions of all the designs are indicated by purple spheres. **(D)** CD spectra of the specified peptides measured at 100 mM concentration, pH 7.4, 25 ± 1°C. **(E)** Percentage of α -helical content of the specified peptides as estimated by dividing the mean residue ellipticity (φ) 222_{obs} by the reported (φ) 222_{obs} for a model helical decapeptide. **(F)** Size exclusion chromatography (SEC) profiles of the specified peptide was filtered with a 0.2 µm filter and then loaded on a Superdex 75 column in buffer V (20 mM HEPES, pH 7.4, 90 mM NaCl). The dashed line indicates the border of the void volume at ~8 ml.

possible interactions with the resin of the size exclusion column.

Screening of Stapled Peptides With a Lipid-Mixing Assay

We first tested the effects of the peptides with an ensemble lipid mixing (fusion) assay with reconstituted neuronal SNAREs and Syt1. Two types of vesicles were reconstituted: plasma-membrane mimicking vesicles containing 1% DiI with reconstituted Stx1 and SNAP-25A (referred to as PM vesicles) and vesicles containing 1% DiD with reconstituted synaptobrevin-2 and Syt1 that mimic synaptic vesicles (referred to as SV vesicles). The two groups of vesicles were mixed at equal molar ratio with final lipid concentration of 0.1 mM, and fluorescence changes of DiI and DiD were recorded. As expected, addition of the non-stapled

peptide P0 has little effect on both Ca²⁺-independent and Ca²⁺triggered lipid mixing, while many of the stapled peptides reduced lipid mixing both in the absence and presence of Ca²⁺ (**Figure 2**). The stapled peptides SP1, SP4, SP9, and SP10 consistently exhibited large inhibition in the lipid mixing assays. Since these four peptides also have the largest α -helical content (**Figure 1D**), this suggests that the helical conformation of the peptides is essential for their inhibitory activity.

Screening of Stapled Peptides With a Single Vesicle Content-Mixing Assay

The ensemble lipid mixing assay is relatively fast and allows one to screen many peptides. However, ensemble lipid mixing experiments have considerable caveats. For example, lipid mixing can occur in the absence of full fusion owing to



FIGURE 2 [Effect of stapled peptides in ensemble lipid mixing assays with neuronal SNAREs and Syt1. (A) The non-stapled peptide P0 has little effect on Ca²⁺-independent ensemble lipid mixing measurements of vesicle-vesicle fusion with SV and PM vesicles (Methods). The two groups of vesicles are mixed at the same molar ratio with a final lipid concentration of 0.1 mM. The time traces show FRET efficiency upon mixing dye-labeled neuronal PM- and SV-vesicles (Methods). The black line is a control without peptide. The green and blue lines indicate the lipid mixing experiments with 10 and 100 µM P0, respectively. (B) Corresponding maximum FRET efficiency within the observation period of 1,000 s. (C) P0 has little effect on Ca²⁺-triggered ensemble lipid mixing measurements of vesicle-vesicle fusion. The two groups of vesicles are mixed at the same molar ratio with a final lipid concentration of 0.1 mM. The time traces show FRET efficiency upon mixing dye-labeled neuronal PM- and SV-vesicles (Methods). The black line is a control without peptide. The green and blue lines indicate the lipid mixing measurements of vesicle-vesicle fusion. The two groups of vesicles are mixed at the same molar ratio with a final lipid concentration of 0.1 mM. The time traces show FRET efficiency upon mixing dye-labeled neuronal PM- and SV-vesicles (Methods). The black line is a control without peptide. The green and blue lines represent the reaction with 10 and 100 µM P0, respectively. (D) Corresponding maximum FRET efficiency within the observation period of 1,000 s. (E) Effect of stapled peptides in absence of Ca²⁺. The two groups of vesicles (SV and PM) were mixed at the same molar ratio with a final lipid concentration of 0.1 mM. The time traces show FRET efficiency upon mixing neuronal dye-labeled PM- and SV-vesicles (Methods). (F) Corresponding maximum FRET efficiency within the observation period of 1,000 s. (G) Effect of stapled peptides in the presence of Ca²⁺. The two groups of vesicles (SV and PM) were mixed at the sa



FIGURE 3 | Stapled peptides inhibit both Ca^{2+} -independent and Ca^{2+} -triggered content mixing with reconstituted neuronal SNAREs and Syt1. (A) Schematic of the single-vesicle content-mixing assay. Neuronal PM: plasma membrane mimic vesicles with reconstituted Stx1A and SNAP-25A; SV: synaptic vesicle mimic with reconstituted VAMP2 and Syt1. After SV—neuronal PM vesicle association, vesicle pairs either undergo Ca^{2+} -independent fusion or remain associated until fusion is triggered by Ca^{2+} addition. 10 µM of each specific stapled peptide (yellow) was added together with SV vesicles and was present in all subsequent stages. For details of the reconstitution and lipid compositions, see Methods in (Lai et al., 2022). (B) Effects of stapled peptides on vesicle association. (C) Corresponding Ca^{2+} -independent fusion probabilities. (D) Corresponding average probabilities of Ca^{2+} -independent fusion events per second (left to right: ***p = 0.00044, ***p = 0.00051, ***p = 0.0022, **p = 0.0012). (E) Corresponding Ca^{2+} -triggered fusion probabilities. (D) Corresponding Ca^{2+} -triggered fusion probabilities of Ca^{2+}-independent fusion events per second (left to right: *p = 0.0044, ***p = 0.00051, ***p = 0.00022, **p = 0.0012). (E) Corresponding Ca^{2+} -triggered fusion probabilities and amplitudes of the first 1-s time bin upon 500 µM Ca^{2+}-injection (F) (left to right: *p = 0.034, *p = 0.017, the cumulative Ca^{2+} -triggered fusion probability within 1 min (G) (left to right: *p = 0.021, *p = 0.039, and the decay rate ($1/\tau$) of the Ca^{2+}-triggered fusion histogram (H). The fusion probabilities and amplitudes were normalized to the number of analyzed neuronal SV—neuronal PM vesicle pairs (Supplementary Table S1). Panels B, D, F, G show box plots and data points for n (indicated below each box plot) independent repeat experiments (Supplementary Table S1): the whiskers show the min and max values (excluding outliers), the box limits are the 25th and 75th pe

metastable hemifusion diaphragms, and FRET efficiency measurements are influenced by differences in vesicle-vesicle association (docking), potentially obscuring the effects of the peptides. A better surrogate for both neurotransmitter release and mucin secretion is a single-vesicle content-mixing assay since it accurately measures content exchange and it is capable of distinguishing between vesicle association, lipid mixing, and content mixing (Kyoung et al., 2011; Diao et al., 2012; Lai et al., 2022). Since a single-vesicle content mixing assay is considerably more complicated and time-consuming, we only tested the subset of the four stapled peptides (SP1, SP4, SP9, SP10) that consistenly showed the largest effects in ensemble lipid mixing experiments (Figure 3A). In the single-vesicle contentmixing assay, SV vesicles are labeled with a soluble fluorescent content dye (sulforhodamine B) at a moderately self-quenching concentration. Content mixing between SV and PM vesicles

results in an increase in volume, and consequently in an increase of content-dye fluorescence intensity. Thus, this assay allows precise measurement of content mixing. Vesicle association was measured by the stable association of a SV vesicle with a surface-tethered PM vesicle, and content mixing data were normalized with respect to the number of associated vesicles. Vesicle association can be influenced by *trans*-SNARE complex formation, Syt1/Syt2–SNARE complex interactions, Syt1/Syt2–syntaxin-SNAP25 subcomplex interactions, and Syt1/Syt2–membrane interactions.

As expected, inclusion of $10 \,\mu\text{M}$ P0 in the fusion assay had no effect on either Ca²⁺-independent or Ca²⁺-triggered fusion (**Figures 3C-H**). In contrast, the four stapled peptides reduced both the cumulative Ca²⁺-independent fusion (up to 60%) and Ca²⁺-triggered fusion (up to 70%) probabilities (**Figures 3C-H**), but they had little effect on vesicle association (**Figure 3B**). When



FIGURE 4 | The quintuple Syt1_QM mutant and omission of Syt1 alleviate the inhibitory effects of stapled peptides. (A) Effects of 10 μ M of each of the specified peptides on vesicle association. (B) Corresponding Ca²⁺-independent fusion probabilities. (C) Corresponding average probabilities of Ca²⁺-independent fusion events per second. (D) Effects of 10 μ M of each of the specified peptides on vesicle association (left to right: **p = 0.0016, *p = 0.017). (E) Corresponding Ca²⁺-independent fusion probabilities. (F) Corresponding average probabilities of Ca²⁺-independent fusion events per second. (G) Corresponding Ca²⁺-triggered fusion probabilities. (H–J) Corresponding Ca²⁺-triggered fusion amplitude of the first 1-s time bin upon 500 μ M Ca²⁺-injection (H), the cumulative Ca²⁺-triggered fusion probability within 1 min (I), and the decay rate (1/ τ) of the Ca²⁺-triggered fusion histogram (J). The fusion probabilities and amplitudes were normalized to the number of analyzed neuronal SV—neuronal SV—neuronal SV pairs (Supplementary Table S1). Panels A,C, D,F,H, I show box plots and data points for n (indicated below each box plot) independent repeat experiments (Supplementary Table S1): the whiskers show the min and max values (excluding outliers), the box limits are the 25th and 75th percentiles, the square point denotes the mean value, and the center line denotes the median. Decay constants (boxes) and error estimates (bars) in panel J computed from the covariance matrix upon fitting the corresponding histograms combining all repeats with a single exponential decay function using the Levenberg-Marquardt algorithm. *p < 0.05, **p < 0.01 by Student's t-test, compared to the experiment without the stapled peptides.

Syt1 was omitted from the reconstituted SV vesicles, none of the four stapled peptides showed any effect on Ca^{2+} -independent fusion probabilities (**Figures 4A–C**), corroborating the notion that the effect of the stapled peptides depends on Syt1. Moreover, there is no effect of the stapled peptides on Ca^{2+} -independent fusion with SNAREs only (**Figures 4A–C**), suggesting that SNARE complex formation is not affected by the presence of the stapled peptides.

We next asked the question whether the inhibition of the fusion probability by the stapled peptides is due to specific interference with the interaction between the neuronal SNARE complex and Syt1 via the primary interface. We performed the single-vesicle content-mixing experiment using the quintuple mutant of Syt1 (Syt1_QM) that specifically disrupts the primary interface between Syt1 and the neuronal SNARE complex (Zhou et al., 2015). With reconstituted Syt1_QM, the stapled peptides had little effect on either Ca²⁺independent or Ca²⁺-triggered fusion (Figures 4E-J). The stapled peptides reduced vesicle association in the presence of Svt1 QM (Figure 4D) which may be caused by binding of the stapled peptides to the polybasic region of Syt1 C2B, and thereby reducing Syt1/Syt2-membrane induced vesicle association in the absence of the primary interface. Together, these data suggest that the inhibitory effect of the stapled peptides on both Ca²⁺-independent and Ca²⁺-triggered fusion is due to specific interference with the primary interface between the SNARE complex and Syt1. Presumably, this interference occurs when the stapled peptides compete with binding of the SNARE complex to the C2B domain of Syt1 (Lai et al., 2022).

Stapled Peptides Inhibit Ca²⁺-Triggered Vesicle Fusion in the Airway System

The residues in the primary interface are conserved across different species for synaptotagmins, SNAP-25, and Stx-1A homologues that are involved in fast synchronous release (Zhou et al., 2015). More generally, the similarity of residues involved in the primary interface between the neuronal system (neuronal SNAREs and Syt1 C2B) and the airway system (airway SNAREs VAMP8, Stx3, SNAP-23, and Syt2 C2B) is also high (Lai et al., 2022). Specifically, the residues that are at or near the primary interface are identical for Syt1/Syt2 except for V292C and identical for SNAP-25A/SNAP-23 except for K40Q, L47I, and V48T.

To confirm if these stapled peptides have a similar inhibitory activity for the airway system, we tested the peptides with a single-vesicle content-mixing assay with reconstituted airway SNAREs and Syt2 (**Figures 5A,B**). Two types of vesicles were reconstituted: plasma-membrane mimicking vesicles with reconstituted Stx3 and SNAP-23 (referred to as airway PM vesicles) and vesicles with reconstituted VAMP8 and Syt2 that mimic mucin-containing secretory granules (referred to as SG vesicles). As expected, and consistent with the results with the neuronal system, the peptides showed no effect on vesicle association (**Figure 5C**). In contrast, the stapled peptides strongly reduced Ca^{2+} -triggered content mixing (**Figures**)

5F-I), along with mild inhibition of Ca^{2+} -independent fusion (**Figures 5D,E**). As a control, the unstapled P0 peptide showed no effect on either Ca^{2+} -independent or Ca^{2+} -triggered fusion. Similar to the neuronal case, when Syt2 was omitted, the stapled peptides showed no significant effect (**Figure 5J-L**), again corroborating the notion that the stapled peptides function by interfering with the primary interface. Together, these results suggest that the inhibition activity of the stapled peptides is conserved for both the neuronal and airway systems.

DISCUSSION

We designed a series of hydrocarbon-stapled peptides that interfere with the primary SNARE/synaptotagmin interface and consequently disrupt Ca²⁺-triggered exocytosis (Figure 1). We found that hydrocarbon staples increase the α -helical conformation of the peptide. The stapled peptides with the hydrocarbon-staple to bridge three amino acids (substitution positions i and i+4) exhibited better helical stabilization with the helical content up to 86% than the other designs (Figures 1D,E). The stapled peptides (SP1, SP4, SP9, SP10) that consistently exhibit large inhibition in lipid mixing assays also have the largest α -helical content (Figures 1, 2). We therefore focused on these four stapled peptides in subsequent studies using a more advanced single-vesicle content-mixing assay that is capable of distinguishing between vesicle association, lipidmixing, and content-mixing (Kyoung et al., 2011; Diao et al., 2012; Lai et al., 2022). The four stapled peptides reduced both Ca²⁺-triggered and Ca²⁺-independent fusion with reconstituted neuronal SNAREs and Syt1 (Figure 3). When Syt1 was omitted, or replaced by a Syt1 mutant (Syt1_QM) that disrupts the primary interface (Zhou et al., 2015), there was no significant effect of the these stapled peptides on single vesicle fusion (Figure 4), suggesting that the inhibitory activity of these peptides is related to the primary interface. The observed inhibition of Ca²⁺-triggered fusion is likely caused by stapled peptide binding to Syt1 in competition with the primary interface (Lai et al., 2022).

Next, we tested the selected stapled peptides with a reconstituted single vesicle fusion assay using airway SNAREs (VAMP8, Stx3, SNAP-23) and Syt2. The four stapled peptides also specifically inhibited Ca²⁺-triggered content mixing while the P0 control peptide showed no effect (Figure 5). Interestingly, the effect of the stapled peptides on Ca²⁺-independent fusion was more modest compared to the neuronal case (compare Figures 4, 5). For a more complete reconstitution involving Munc18 and Munc13 and using one of the stapled peptides (SP9), the effect on Ca²⁺-triggered fusion was also more pronounced than the effect on Ca²⁺-independent fusion (Lai et al., 2022). A possible explanation is that the airway system might lack complexin, a factor that both inhibits Ca²⁺-independent fusion, and activates Ca²⁺-triggered fusion (Lai et al., 2014; Maximov et al., 2009). Thus, since our "simple" reconstitution with reconstituted SNAREs and Syt1 (Figures 2-4) lacks complexin, we may observe an enhanced effect of the stapled peptides on Ca2+-independent



FIGURE 5 | Stapled peptides inhibit Ca²⁺-triggered content mixing with reconstituted airway epithelial SNAREs and Syt2. (A) SDS-PAGE of airway PM and SG vesicles with reconstituted airway SNAREs and Syt2. A chymotrypsin digest was used to determine the proper directionality of the reconstituted membrane proteins. For details of the reconstitution and lipid compositions, see Methods in (Lai et al., 2022). (B) Schematic of the single vesicle content mixing assay. Airway PM: plasma membrane mimic vesicles with reconstituted airway Stx3 and SNAP-23; SG: secretory granule mimics with reconstituted VAMP8 and Syt2. After SG-airway PM vesicle association, vesicle pairs either undergo Ca²⁺-independent fusion or remain associated until fusion is triggered by Ca²⁺ addition. 10 µM of each specific stapled peptide (yellow) was added together with SG vesicles and was present during all subsequent stages. (C) Effects of stapled peptides on vesicle association. (D) Corresponding Ca²⁺-independent fusion probabilities. (E) Corresponding average probabilities of Ca²⁺-independent fusion events per second (left to right: **p = 0.0062, **p = 0.0082, *p = 0.014, *p = 0.034). (F) Corresponding Ca²⁺-triggered fusion probabilities. (G-I) Corresponding Ca²⁺-triggered fusion amplitudes of the first 1-s time bin upon 500 µM Ca²⁺-injection (G) (left to right: *p = 0.036, **p = 0.0033, *p = 0.012, **p = 0.0037), the cumulative Ca²⁺-triggered fusion probability within 1 min (H) (left to right: **p = 0.0017, **p = 0.0014, ** 0.0018, **p = 0.0011), and the decay rate (1/ τ) of the Ca²⁺-triggered fusion histogram (I). (J-L) the stapled peptides have no effect on vesicle fusion mediated by airway SNAREs alone. (J) Effects of 10 µM of each of the specified peptides on vesicle association using the assay described above. (K) Corresponding Ca²⁺-independent fusion probabilities. (L) Corresponding average probabilities of Ca²⁺-independent fusion events per second. Panels C,E,G,H, J, L show box plots and data points for n (indicated below each box plot) independent repeat experiments (Supplementary Table S1): the whiskers show the min and max values (excluding outliers), the box limits are the 25th and 75th percentiles, the square point denotes the mean value, and the center line denotes the median. Decay constants (boxes) and error estimates (bars) in panel I computed from the covariance matrix upon fitting the corresponding histograms combining all repeats with a single exponential decay function using the Levenberg-Marquardt algorithm. *p < 0.05, **p < 0.01 by Student's t-test, compared to the experiment without the stapled peptides.

fusion, whereas for the airway system this function of complexin may not be required. In this context, it will also be desirable to test other sequences and strategies in future work, including the SNAP-23 sequence itself that might strengthen (or weaken) the interaction with Syt1 or Syt2 considering the K40Q, L47I, and V48T substitutions. We also note that Ca^{2+} -independent

fusion as observed with our assays may be distinct from spontaneous neurotransmitter release and baseline mucin secretion since they may use other high-affinity Ca^{2+} -sensors (Kavalali, 2015).

In summary, our results indicate that the primary interface between the airway SNARE complex and Syt2 is also essential for Ca²⁺-triggered exocytosis. Moreover, the biological function of the primary interface between SNAREs and synaptotagmins is conserved for both synaptic neurotransmitter release and airway mucin secretion. We recently tested one of the stapled peptides (SP9) in cultured human airway epithelial cells and mouse airway epithelium by conjugation to cell penetrating peptides where it markedly and specifically reduced stimulated mucin secretion in both systems, and substantially attenuated mucus occlusion of mouse airways (Lai et al., 2022). Taken together, stapled peptides that disrupt Ca²⁺-triggered membrane fusion may allow therapeutic modulation of mucin secretory pathways and neurotransmitter release. Moreover, our inhibition strategy could be useful for a wide range of Ca²⁺-triggered endocrine and exocrine secretion systems.

METHODS

Protein Expression and Purification

We used the same constructs and protocols to purify cysteinefree syntaxin-1A (Stx1), syntaxin-3 (Stx3), SNAP-25A, SNAP-23, VAMP2, VAMP8, Syt-1, Syt-2, and Syt-2_QM, as described in refs. (Lai et al., 2017; Lai et al., 2022). The protein sample concentrations were measured by UV absorption at 280 nm, aliquots were flash frozen in liquid nitrogen and stored at -80° C.

Peptide Synthesis

All the stapled peptides (SP1, SP2, SP3, SP4, SP5 SP6, SP7, SP8, SP9, SP10, SP11, SP12) and the non-stapled peptide P0 were synthesized and purified by Vivitide (formerly New England Peptide, Gardner, United States). Peptide synthesis was carried out using solid phase peptide synthesis and Fmoc chemistry similar to ref. (Lai et al., 2022). Briefly, these peptides were cleaved using trifluoroacetic acid and standard scavengers. The peptides were purified using reverse phase high pressure liquid chromatography. For the stapled peptides, α , α -disubstituted non-natural amino acids of olefinic side chains were synthesized (S5-S stereochemistry, bridging 5 amino acids; R8-R stereochemistry, bridging 8 amino acids). The hydrocarbon-staples were made via Grubbs catalyst (Schafmeister et al., 2000). For all stapled peptides, the N-termini were acetylated and the C-termini amidated. For more details of the synthesis see ref. (Lai et al., 2022).

All peptides were purified to >90%–95% purity, and quality control was performed by liquid chromatography mass spectrometry (LC-MS) by the manufacturer (**Supplementary Figures S1–S12**). Subsequently, the peptides were lyophilized and shipped. The LC-MS quality control data indicate that the peptides have the predicted molecular weight according to their chemical composition, suggesting that the synthesized peptides have the correct sequence and properly formed staples.

For each group of experiments, aliquots of peptide powder were directly dissolved in the specified buffers at $\sim 1 \text{ mM}$ concentration using a vortexer, and then diluted to the specified peptide concentrations. The concentration of the stock solution was confirmed by absorption measurement at 205 nm using a Nanodrop instrument (Thermo Fisher, Inc.).

CD Spectroscopy

The CD spectra were measured with an AVIV stop-flow CD spectropolarimeter at 190–250 nm using a cell with a 1 mm path-length. The sample containing 100 mM of synthesized peptides in PBS buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 2 mM KH2PO4, pH 7.4) was measured at 20°C. For the correction of the baseline error, the signal from a blank run with PBS buffer was subtracted from all the experimental spectra. The α -helical content of each peptide was calculated by dividing the mean residue ellipticity (φ) 222_{obs} by the reported (φ) 222_{obs} for a model helical decapeptide (Yang et al., 1986).

Vesicle Reconstitution

For the ensemble lipid-mixing assay, the lipid composition of SV vesicles was phosphatidylcholine (PC) (46%), phosphatidylethanolamine (PE) (20%), phosphatidylserine (PS) (12%), cholesterol (20%), and 1,1'-dioctadecyl-3,3,3',3'tetramethylindodicarbocyanine perchlorate (DiD) (2%). For PM vesicles the lipid composition was Brain Total Lipid Extract (Avanti Polar Lipids) supplemented with 3.5 mol% PIP2, 0.1 mol% biotinylated phosphatidylethanolamine (PE) and 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI).

For single-vesicle content-mixing assays, the lipid composition of SV vesicles, SG vesicles, VAMP2-only, or VAMP8-only vesicles was phosphatidylcholine (PC) (48%), phosphatidylethanolamine (PE) (20%), phosphatidylserine (PS) (12%), and cholesterol (20%). For PM vesicles, the lipid composition was Brain Total Lipid Extract (Avanti Polar Lipids) supplemented with 3.5 mol% PIP2, and 0.1 mol% biotinylated phosphatidylethanolamine (PE). The detailed reconstitution protocols for the vesicles are described in refs. (Lai et al., 2017; Lai et al., 2022).

Ensemble Lipid Mixing

Protein-reconstituted PM and SV vesicles were mixed at a molar ratio of 1:1, both at 0.1 mM lipid concentration. In the ensemble lipid mixing assay, the SNARE protein concentrations are ~ 0.5 μ M, while the peptide concentrations are 10 and 100 μ M, so the peptide:SNARE ratios are 1:20 or 1:200, respectively. Lipid-mixing is measured as the fluorescent emission (at 670 nm) of DiD dyes in SV vesicles *via* fluorescence resonance energy transfer (FRET) from DiI dyes in PM vesicles that were excited by 530 nm laser light. The fluorescence intensities were monitored in two channels at 570 and 670 nm,

respectively. Fluorescence changes were recorded with a Varian Cary Eclipse model fluorescence spectrophotometer using a quartz cell of $100 \,\mu$ l with a 5 mm path length. All measurements were performed at 35°C.

Single Vesicle-Vesicle Content Mixing Assay, Instrument Setup, and Data Analysis

Details for the single-vesicle content-mixing assay are described in (Lai et al., 2022). In the single vesicle content mixing assay, the peptide concentration is $10 \,\mu\text{M}$ in the chamber. The PM vesicles are tethered to the surface with ~100 syntaxin molecules per vesicle (Kyoung et al., 2011), so considering the two-dimensional local concentration effect, the peptide:SNARE ratio is expected to be very high.

Quantification and Statistical Analysis

Origin, Matlab, and Prism were used for the generation of all curves and graphs. The single-vesicle content-mixing experiments were repeated at least three times with different protein preps and vesicle reconstitutions (**Supplementary Table S1**) and properties were calculated as mean \pm SEM. The two-tailed Student's t-test was used to test statistical significance in **Figures 3–5** with respect to the specified reference experiment.

Software and Code

The data for the ensemble lipid mixing experiments were collected by a program provided by the manufacturer of the Cary Eclipse instrument. The data for the single-vesicle content-mixing experiments were collected by using the smCamera program developed by Taekjip Ha, Johns Hopkins University, Baltimore. For the ensemble lipid mixing experiments, the single-vesicle content-mixing experiments and the circular dichroism experiments, OriginPro 8 and Matlab-2021b were used. Pymol 2.5.1 was used for visualization. MATLAB analysis scripts for the single-vesicle fusion experiments and for the smCamera file conversions are available in the Zenodo repository https://doi.org/10.5281/zenodo.6370585.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in the Dryad repository https://doi.org/10.5061/dryad.x3ffbg7mp.

AUTHOR CONTRIBUTIONS

YL, BD, and AB designed experiments. YL performed fusion and CD experiments. YL, PJ, BC, and QZ performed inhibitor design. JL and JP wrote Matlab scripts to analyse the fusion experiments. RP and LE assisted with protein purification. YL, BD, and AB wrote the manuscript.

FUNDING

This work was supported by the National Institutes of Health (NIH) (R37MH63105 to AB; R01 HL129795 and R21 AI137319 to BD), and the Cystic Fibrosis Foundation (DICKEY18G0 and DICKEY19P0). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH. This article is subject to HHMI's Open Access to Publications policy. HHMI lab heads have previously granted a nonexclusive CC BY 4.0 license to the public and a sublicensable license to HHMI in their research articles. Pursuant to those licenses, the author-accepted manuscript of this article can be made freely available under a CC BY 4.0 license immediately upon publication.

ACKNOWLEDGMENTS

We thank Roberto Adachi, Melissa Singh, Thomas Südhof, Tony Velkov, Chuchu Wang for stimulating discussions, Heawon Chong and colleagues at Vivitide Inc. for their expertise in peptide synthesis and collaborative efforts.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.891041/full#supplementary-material

Supplementary Figure S1 | Quality control data for the P0 peptide provided by Vivitide Inc.

Supplementary Figure S2 | Quality control data for the P1 peptide provided by Vivitide Inc.

Supplementary Figure S3 | Quality control data for the P2 peptide provided by Vivitide Inc.

Supplementary Figure S4 | Quality control data for the P3 peptide provided by Vivitide Inc.

Supplementary Figure S5 | Quality control data for the P4 peptide provided by Vivitide Inc. Quality control data for the P5 peptide provided by Vivitide Inc.

Supplementary Figure S6 | Quality control data for the P6 peptide provided by Vivitide Inc.

Supplementary Figure S7 | Quality control data for the P7 peptide provided by Vivitide Inc.

Supplementary Figure S8 | Quality control data for the P8 peptide provided by Vivitide Inc.

Supplementary Figure S9 | Quality control data for the P9 peptide provided by Vivitide Inc.

Supplementary Figure S10 | Quality control data for the P10 peptide provided by Vivitide Inc.

Supplementary Figure S11 | Quality control data for the P11 peptide provided by Vivitide Inc.

Supplementary Figure S12 | Quality control data for the P12 peptide provided by Vivitide Inc.

Supplementary Table S1 | Data summary table for the single vesicle fusion experiments.

REFERENCES

- Boucher, R. C. (2019). Muco-Obstructive Lung Diseases. N. Engl. J. Med. 380, 1941–1953. doi:10.1056/nejmra1813799
- Brunger, A. T., Choi, U. B., Lai, Y., Leitz, J., and Zhou, Q. (2018). Molecular Mechanisms of Fast Neurotransmitter Release. Annu. Rev. Biophys. 47, 469–497. doi:10.1146/annurev-biophys-070816-034117
- Davis, C. W., and Dickey, B. F. (2008). Regulated Airway Goblet Cell Mucin Secretion. Annu. Rev. Physiol. 70, 487–512. doi:10.1146/annurev.physiol.70. 113006.100638
- Diao, J., Grob, P., Cipriano, D. J., Kyoung, M., Zhang, Y., Shah, S., et al. (2012). Synaptic Proteins Promote Calcium-Triggered Fast Transition from Point Contact to Full Fusion. *Elife* 1, e00109. doi:10.7554/eLife.00109
- Fahy, J. V., and Dickey, B. F. (2010). Airway Mucus Function and Dysfunction. N. Engl. J. Med. 363, 2233–2247. doi:10.1056/NEJMra0910061
- Jaramillo, A. M., Azzegagh, Z., Tuvim, M. J., and Dickey, B. F. (2018). Airway Mucin Secretion. Ann. Am. Thorac. Soc. 15, S164–S170. doi:10.1513/ AnnalsATS.201806-371AW
- Jaramillo, A. M., Piccotti, L., Velasco, W. V., Delgado, A. S. H., Azzegagh, Z., Chung, F., et al. (2019). Different Munc18 Proteins Mediate Baseline and Stimulated Airway Mucin Secretion. JCI Insight 4, e124815. doi:10.1172/jci.insight.124815
- Jones, L. C., Moussa, L., Fulcher, M. L., Zhu, Y., Hudson, E. J., O'Neal, W. K., et al. (2012). VAMP8 Is a Vesicle SNARE That Regulates Mucin Secretion in Airway Goblet Cells. J. Physiol. 590, 545–562. doi:10.1113/jphysiol.2011.222091
- Kavalali, E. T. (2015). The Mechanisms and Functions of Spontaneous Neurotransmitter Release. Nat. Rev. Neurosci. 16, 5–16. doi:10.1038/nrn3875
- Kim, K., Petrova, Y. M., Scott, B. L., Nigam, R., Agrawal, A., Evans, C. M., et al. (2012). Munc18b Is an Essential Gene in Mice Whose Expression Is Limiting for Secretion by Airway Epithelial and Mast Cells. *Biochem. J.* 446, 383–394. doi:10.1042/BJ20120057
- Kyoung, M., Srivastava, A., Zhang, Y., Diao, J., Vrljic, M., Grob, P., et al. (2011). In Vitro System Capable of Differentiating Fast Ca²⁺-Triggered Content Mixing From Lipid Exchange for Mechanistic Studies of Neurotransmitter Release. Proc. Natl. Acad. Sci. U S A. 108, E304–E313. doi:10.1073/pnas.1107900108
- Lai, Y., Diao, J., Cipriano, D. J., Zhang, Y., Pfuetzner, R. A., Padolina, M. S., et al. (2014). Complexin Inhibits Spontaneous Release and Synchronizes Ca²⁺-Triggered Synaptic Vesicle Fusion by Distinct Mechanisms. *Elife* 3, e03756. doi:10.7554/eLife.03756
- Lai, Y., Choi, U. B., Leitz, J., Rhee, H. J., Lee, C., Altas, B., et al. (2017). Molecular Mechanisms of Synaptic Vesicle Priming by Munc13 and Munc18. *Neuron* 95, 591–607.e10. doi:10.1016/j.neuron.2017.07.004
- Lai, Y., Fois, G., Flores, J. R., Tuvim, M. J., Zhou, Q., Yang, K., et al. (2022). Inhibition of Calcium-Triggered Secretion by Hydrocarbon-Stapled Peptides. *Nature* 603, 949–956. doi:10.1038/s41586-022-04543-1
- Maximov, A., Tang, J., Yang, X., Pang, Z. P., and Südhof, T. C. (2009). Complexin Controls the Force Transfer From SNARE Complexes to Membranes in Fusion. *Science* 323, 516–521. doi:10.1126/science.1166505
- Ren, B., Azzegagh, Z., Jaramillo, A. M., Zhu, Y., Pardo-Saganta, A., Bagirzadeh, R., et al. (2015). SNAP23 Is Selectively Expressed in Airway Secretory Cells and Mediates Baseline and Stimulated Mucin Secretion. *Biosci. Rep.* 35, e00220. doi:10.1042/ BSR20150004
- Riento, K., Galli, T., Jansson, S., Ehnholm, C., Lehtonen, E., and Olkkonen, V. M. (1998). Interaction of Munc-18-2 With Syntaxin 3 Controls the Association of

Apical SNARES in Epithelial Cells. J. Cel. Sci. 111 (Pt 17), 2681–2688. doi:10. 1242/jcs.111.17.2681

- Rothman, J. E. (2014). The Principle of Membrane Fusion in the Cell (Nobel Lecture). Angew. Chem. Int. Ed. 53, 12676–12694. doi:10.1002/anie. 201402380
- Schafmeister, C. E., Po, J., and Verdine, G. L. (2000). An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides. J. Am. Chem. Soc. 122, 5891–5892. doi:10.1021/ja000563a
- Südhof, T. C. (2013). Neurotransmitter Release: The Last Millisecond in the Life of a Synaptic Vesicle. *Neuron* 80, 675–690. doi:10.1016/j.neuron.2013. 10.022
- Sutton, R. B., Fasshauer, D., Jahn, R., and Brunger, A. T. (1998). Crystal Structure of a SNARE Complex Involved in Synaptic Exocytosis at 2.4 Å Resolution. *Nature* 395, 347–353. doi:10.1038/26412
- Tuvim, M. J., Mospan, A. R., Burns, K. A., Chua, M., Mohler, P. J., Melicoff, E., et al. (2009). Synaptotagmin 2 Couples Mucin Granule Exocytosis to Ca²⁺ Signaling From Endoplasmic Reticulum. *J. Biol. Chem.* 284, 9781–9787. doi:10.1074/jbc. M807849200
- Voleti, R., Jaczynska, K., and Rizo, J. (2020). Ca²⁺-Dependent Release of Synaptotagmin-1 From the SNARE Complex on Phosphatidylinositol 4,5-Bisphosphate-Containing Membranes. *Elife* 9, e57154. doi:10.7554/eLife. 57154
- Yang, J. T., Wu, C. S., and Martinez, H. M. (1986). Calculation of Protein Conformation From Circular Dichroism. *Methods Enzymol.* 130, 208–269. doi:10.1016/0076-6879(86)30013-2
- Zhou, Q., Lai, Y., Bacaj, T., Zhao, M., Lyubimov, A. Y., Uervirojnangkoorn, M., et al. (2015). Architecture of the Synaptotagmin-SNARE Machinery for Neuronal Exocytosis. *Nature* 525, 62–67. doi:10.1038/nature14975
- Zhou, Q., Zhou, P., Wang, A. L., Wu, D., Zhao, M., Südhof, T. C., et al. (2017). The Primed SNARE-Complexin-Synaptotagmin Complex for Neuronal Exocytosis. *Nature* 548, 420–425. doi:10.1038/nature23484
- Zhu, Y., Ehre, L. H., Abdullah, M., Sheehan, B. F., Roy, C. W., Evans, C. M., et al. (2008). Munc13-2-/-Baseline Secretion Defect Reveals Source of Oligomeric Mucins in Mouse Airways. J. Physiol. 586, 1977–1992. doi:10.1113/jphysiol. 2007.149310

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lai, Tuvim, Leitz, Peters, Pfuetzner, Esquivies, Zhou, Czako, Cross, Jones, Dickey and Brunger. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.